Full text biomedical articles

Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease.

V K Puri, A Rawat, A Sharma, A Mehrotra, M Hasan, K Shanker, M Verma, J N Sinha, K P Bhargava
Br Med J (Clin Res Ed) 1986 Sep 6; 293(6547): 591–593. doi: 10.1136/bmj.293.6547.591

Summary   |   Page Browse   |   PDF–578K   |   Cite

Sulphinpyrazone metabolism during long-term therapy.

A K Pedersen, P Jakobsen
Br J Clin Pharmacol. 1981 Jun; 11(6): 597–603. doi: 10.1111/j.1365-2125.1981.tb01176.x

Summary   |   Page Browse   |   PDF–833K   |   Cite

Hazards of sulphinpyrazone.

S Ahmad
Br Med J. 1979 Feb 3; 1(6159): 344–345. doi: 10.1136/bmj.1.6159.344-d

Summary   |   Page Browse   |   PDF–540K   |   Cite

Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

I D Bradbrook, V A John, P J Morrison, H J Rogers, R G Spector
Br J Clin Pharmacol. 1982 Feb; 13(2): 177–185. doi: 10.1111/j.1365-2125.1982.tb01353.x

Summary   |   Page Browse   |   PDF–1.0M   |   Cite

Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.

D J Birkett, J O Miners, J Attwood
Br J Clin Pharmacol. 1983 May; 15(5): 567–569. doi: 10.1111/j.1365-2125.1983.tb02093.x

Summary   |   Page Browse   |   PDF–413K   |   Cite

The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.

L Viinikka, J Toivanen, O Ylikorkala
Br J Clin Pharmacol. 1982 Sep; 14(3): 456–458. doi: 10.1111/j.1365-2125.1982.tb02009.x

Summary   |   Page Browse   |   PDF–456K   |   Cite

Effects of chronic metoprolol and sulphinpyrazone on human lymphocyte beta-adrenoceptors.

A De Blasi, M Cortellaro, C Costantini
Br J Clin Pharmacol. 1984 Jul; 18(1): 45–50. doi: 10.1111/j.1365-2125.1984.tb05020.x

Summary   |   Page Browse   |   PDF–656K   |   Cite

Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function.

R G Wilcox, D Richardson, J R Hampton, J R Mitchell, D C Banks
Br Med J. 1980 Aug 23; 281(6239): 531–534. doi: 10.1136/bmj.281.6239.531

Summary   |   Page Browse   |   PDF–774K   |   Cite

A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone.

M. M. Kubik, S. G. Richardson
Postgrad Med J. 1987 May; 63(739): 351–356. doi: 10.1136/pgmj.63.739.351

Summary   |   Page Browse   |   PDF–808K   |   Cite

A protective effect of sulphinpyrazone against coronary occlusion-induced shortening of myocardial refractory periods in the rat.

B. J. Northover
Br J Pharmacol. 1986 May; 88(1): 141–148. doi: 10.1111/j.1476-5381.1986.tb09480.x

Summary   |   Page Browse   |   PDF–1.1M   |   Cite

Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells.

J L Gordon, J D Pearson
Br J Pharmacol. 1978 Dec; 64(4): 481–483. doi: 10.1111/j.1476-5381.1978.tb17308.x

Summary   |   Page Browse   |   PDF–418K   |   Cite

A direct protective effect of sulphinpyrazone on ischaemic and reperfused rat hearts.

M. Karmazyn
Br J Pharmacol. 1984 Sep; 83(1): 221–226. doi: 10.1111/j.1476-5381.1984.tb10138.x

Summary   |   Page Browse   |   PDF–746K   |   Cite

Haemodynamic effects of sulphinpyrazone in experimental myocardial ischaemia.

D. C. Russell
Br J Pharmacol. 1981 Jan; 72(1): 5–7. doi: 10.1111/j.1476-5381.1981.tb09095.x

Summary   |   Page Browse   |   PDF–425K   |   Cite

Biphasic sulphinpyrazone-warfarin interaction.

G G Nenci, G Agnelli, M Berrettini
Br Med J (Clin Res Ed) 1981 Apr 25; 282(6273): 1361–1362. doi: 10.1136/bmj.282.6273.1361

Summary   |   Page Browse   |   PDF–544K   |   Cite

Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.

B Nunn, F J James
Br J Clin Pharmacol. 1980 Mar; 9(3): 239–245. doi: 10.1111/j.1365-2125.1980.tb04833.x

Summary   |   Page Browse   |   PDF–868K   |   Cite

Sulphinpyrazone and warfarin after myocardial infarction.

J A Tulloch, T C Marr
Br Med J. 1979 Jul 14; 2(6182): 133. doi: 10.1136/bmj.2.6182.133

Summary   |   Page Browse   |   PDF–276K   |   Cite

Verapamil disposition--effects of sulphinpyrazone and cimetidine.

L M Wing, J O Miners, K J Lillywhite
Br J Clin Pharmacol. 1985 Mar; 19(3): 385–391. doi: 10.1111/j.1365-2125.1985.tb02658.x

Summary   |   Page Browse   |   PDF–799K   |   Cite

Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis

Alexander F. Flynn, M. Gordon Joyce, Rebekah T. Taylor, Sasisekhar Bennuru, Alyssa R. Lindrose, Spencer L. Sterling, C. Paul Morris, Thomas B. Nutman, Edward Mitre
PLoS Negl Trop Dis. 2019 Sep; 13(9): e0007687. Published online 2019 Sep 12. doi: 10.1371/journal.pntd.0007687

Article   |   PubReader   |   PDF–2.1M   |   Cite

Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.

K. S. Hilliker, R. A. Roth
Br J Pharmacol. 1984 Jun; 82(2): 375–380. doi: 10.1111/j.1476-5381.1984.tb10772.x

Summary   |   Page Browse   |   PDF–805K   |   Cite

Sulphinpyrazone increases lymphocyte beta-adrenoceptors in man.

A De Blasi, S Cotecchia
Br J Clin Pharmacol. 1984 Dec; 18(6): 963–964. doi: 10.1111/j.1365-2125.1984.tb02572.x

Summary   |   Page Browse   |   PDF–246K   |   Cite